These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12702130)

  • 1. Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.
    Hejdeman B; Leandersson AC; Fredriksson EL; Sandström E; Wahren B; Bratt G
    HIV Med; 2003 Apr; 4(2):101-10. PubMed ID: 12702130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
    Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
    J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.
    Gudmundsdotter L; Boström AC; Burton C; Rosignoli G; Sandström E; Hejdeman B; Wahren B; Imami N; Gotch F
    Vaccine; 2008 Sep; 26(40):5107-10. PubMed ID: 18455841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy.
    Hejdeman B; Boström AC; Matsuda R; Calarota S; Lenkei R; Fredriksson EL; Sandström E; Bratt G; Wahren B
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):860-70. PubMed ID: 15320990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.
    Pialoux G; Quercia RP; Gahery H; Daniel N; Slama L; Girard PM; Bonnard P; Rozenbaum W; Schneider V; Salmon D; Guillet JG
    Clin Vaccine Immunol; 2008 Mar; 15(3):562-8. PubMed ID: 18184824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
    Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
    J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.
    Rigaud M; Borkowsky W; Muresan P; Weinberg A; Larussa P; Fenton T; Read JS; Jean-Philippe P; Fergusson E; Zimmer B; Smith D; Kraimer J;
    J Infect Dis; 2008 Oct; 198(8):1123-30. PubMed ID: 18752430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.
    Kroon FP; Rimmelzwaan GF; Roos MT; Osterhaus AD; Hamann D; Miedema F; van Dissel JT
    AIDS; 1998 Dec; 12(17):F217-23. PubMed ID: 9863863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection.
    Lange CG; Lederman MM; Medvik K; Asaad R; Wild M; Kalayjian R; Valdez H
    AIDS; 2003 Sep; 17(14):2015-23. PubMed ID: 14502004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
    Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
    Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination.
    Farquhar C; Wamalwa D; Selig S; John-Stewart G; Mabuka J; Majiwa M; Sutton W; Haigwood N; Wariua G; Lohman-Payne B
    Pediatr Infect Dis J; 2009 Apr; 28(4):295-9. PubMed ID: 19258919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
    Valentine FT; Kundu S; Haslett PA; Katzenstein D; Beckett L; Spino C; Borucki M; Vasquez M; Smith G; Korvick J; Kagan J; Merigan TC
    J Infect Dis; 1996 Jun; 173(6):1336-46. PubMed ID: 8648205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.
    Wendland T; Furrer H; Vernazza PL; Frutig K; Christen A; Matter L; Malinverni R; Pichler WJ
    AIDS; 1999 Oct; 13(14):1857-62. PubMed ID: 10513643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.